Lido Advisors
LUCD icon

Lido Advisors’s Lucid Diagnostics LUCD Stock Holding History

Lido Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$478K Buy
446,739
+63,657
+17% +$68.6K ﹤0.01% 1505
2026
Q1 		$441K Hold
383,082
– – ﹤0.01% 1366
2025
Q4 		$387K Hold
383,082
– – ﹤0.01% 1427
2025
Q3 		$387K Hold
383,082
– – ﹤0.01% 1351
2025
Q2 		$441K Hold
383,082
– – ﹤0.01% 1154
2025
Q1 		$571K Buy
383,082
+243,066
+174% +$292K ﹤0.01% 977
2024
Q4 		$115K Buy
140,016
+40,000
+40% +$35.3K ﹤0.01% 1435
2024
Q3 		$81.5K Buy
100,016
+32,000
+47% +$26.2K ﹤0.01% 1409
2024
Q2 		$55.8K Buy
+68,016
New +$57.7K ﹤0.01% 1374

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Lido Advisors's LUCD Position: Q2 2026 in Review

Lido Advisors increased its Lucid Diagnostics (LUCD) stake by 17% in Q2 2026, buying an estimated $68.6K and bringing the position to 446,739 shares worth $478K. The position accounts for ﹤0.01% of the portfolio, ranked #1505.

Lido Advisors first reported a position in LUCD in Q2 2024 and has held it in 9 quarters since. The position peaked at $571K in Q1 2025. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Lido Advisors held 446,739 shares of Lucid Diagnostics worth $478K as of Q2 2026.
  • Lido Advisors bought 63,657 Lucid Diagnostics shares in Q2 2026, an estimated $68.6K.
  • Lucid Diagnostics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1505 holding.
  • Lido Advisors first reported a position in Lucid Diagnostics in Q2 2024 and has held it in 9 quarters since.
  • Lido Advisors's Lucid Diagnostics position peaked at $571K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.